title: Imiquimod for the treatment of genital warts: a quantitative systematic review.
abstract: OBJECTIVE
  To review published randomised controlled trials to assess the benefit and harm of imiquimod in the treatment of external genital warts.
  
  
  METHODS
  MEDLINE (1966 - December 2000), Cochrane Library (Issue 3, 2000) and PubMed (December 15, 2000), review articles and reference lists.
  
  
  METHODS
  Included studies had to be randomised trials of imiquimod, to be full published papers, and to have a comparison group. Quality of trial reporting was assessed. Relative benefit and number needed to treat were calculated for the main outcomes of wart clearance at the end of therapy, of at least 50% reduction in wart area, and of complete clearance at the end of treatment and no recurrence of warts during a follow-up period, as well as for adverse effect withdrawal or lack of efficacy withdrawal.
  
  
  RESULTS
  There were six trials, all with quality scores of 3 (out of 5) or greater. In five trials with HIV-negative patients complete clearance of warts at the end of treatment occurred in 51% of patients treated with imiquimod 2% or 5% cream and 6% of placebo treated patients. The number needed to treat was 2.2 (95% confidence interval 2.0 to 2.6). In four trials at least 50% wart area reduction occurred with 72% of patients treated with imiquimod 5% cream and 20% of placebo treated patients. The number needed to treat was 1.9 (1.7 to 2.2). In three trials complete clearance of warts at the end of treatment plus no recurrence occurred in 37% of patients treated with imiquimod 5% cream and 4% of those treated with placebo. The number needed to treat was 3.0 (2.5 to 3.8). Adverse event withdrawal was rare and no more likely with imiquimod than with placebo. Imiquimod was not effective in one trial in HIV-positive patients.
  
  
  CONCLUSIONS
  The evidence base for imiquimod in treating genital warts is of high quality and the necessary size from which to draw useful conclusions. Imiquimod is effective in home application, though not in patients with HIV infection with the evidence presently available.
authors.affiliation: Pain Research and Nuffield Department of Anaesthetics University of Oxford, The Churchill, Headington Oxford OX3 7LJ, UK. andrew.moore@pru.ox.ac.uk
authors.forename: R A
authors.initials: RA
authors.lastname: Moore
authors.forename: J E
authors.initials: JE
authors.lastname: Edwards
authors.forename: J
authors.initials: J
authors.lastname: Hopwood
authors.forename: D
authors.initials: D
authors.lastname: Hicks
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000821:virology; D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003218:Condylomata Acuminata / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000634:Aminoquinolines; D007369:Interferon Inducers; D000077271:Imiquimod